US Bioservices is now dispensing RYDAPT

The U.S. Food and Drug Administration recently approved RYDAPT (midostaurin) for the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM).